Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Price: $0.92 -1.08%
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Join SI Premium – FREE
Needham & Company analyst Chad Messer raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $15.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Okta, Inc (OKTA) PT Raised to $235 at DA Davidson Following Oktane 2026
- Kinross Gold (K:CN) (KGC) PT Lowered to Cdn$48 at BMO Capital
- TransUnion (TRU) PT Lowered to $80 at UBS as CFO Transition Announced
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
